Premium
Potential impact of introducing a nonavalent HPV vaccination
Author(s) -
Bogani Giorgio,
Taverna Francesca,
Lombardo Claudia,
Signorelli Mauro,
Chiappa Valentina,
Casarin Jvan,
Scaffa Cono,
Leone Roberti Maggiore Umberto,
Recalcati Dario,
Ditto Antonino,
Martinelli Fabio,
Borghi Chiara,
Perotto Stefania,
Ferrero Simone,
Lorusso Domenica,
Raspagliesi Francesco
Publication year - 2018
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1002/ijgo.12546
Subject(s) - medicine , vaccination , virology
Objective To test the theoretical utility of incorporating nonavalent vaccination against HPV into a clinical setting. Methods The present retrospective study included data from consecutive patients who underwent HPV ‐ DNA testing between January 1, 1998, and December 31, 2015. Changes in the prevalence of different HPV types were assessed during three periods (T1, 1998–2003; T2, 2004–2009; and T3, 2010–2015) using XY analysis. Results The study included a total of 13 665 patients. Overall, 1361, 5130, and 7174 patients were included in the T1, T2, and T3 periods, respectively. The quadrivalent vaccine would have potentially protected against HPV in 71.5% (973/1361), 46.5% (2385/5130), and 26.5% (1901/7174) of patients in T1, T2, and T3, respectively ( P <0.001 for trend). The nonavalent vaccine could have protected against HPV in 92.5% (1259/1361), 72.3% (3709/5130), and 58.1% (4168/7174) of patients in T1, T2, and T3, respectively ( P <0.001 for trend). The proportion of patients with genital dysplasia grade 2+ who did not have infections with HPV genotypes covered by the quadrivalent or nonavalent vaccines increased across the three periods ( P <0.001 for trend). For all study periods, the protection provided by the nonavalent vaccine would have been superior to the quadrivalent vaccine (χ 2 test P <0.001). Conclusion The introduction of a nonavalent vaccine could improve protection against HPV infections and HPV ‐related genital dysplasia.